Overexpression of KPNA2 correlates with poor prognosis in patients with gastric adenocarcinoma

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 1021-1026

  Li, Chen ^a   Ji, Lv ^b   Ding, Zhong Yang ^c   Zhang, Qian De ^d   Huang, Guo Rong ^c  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Gastric adenocarcinoma; KPNA2; Prognosis

Indexed keywords

KARYOPHERIN ALPHA; KARYOPHERIN ALPHA2; UNCLASSIFIED DRUG; KPNA2 PROTEIN, HUMAN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ADENOCARCINOMA; STOMACH MUCOSA; SURVIVAL TIME; ADENOCARCINOMA; CANCER STAGING; CASE CONTROL STUDY; COLLOID CARCINOMA; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; LYMPH NODE; METABOLISM; MIDDLE AGED; MORTALITY; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNET RING CARCINOMA; STOMACH TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ALPHA KARYOPHERINS; CARCINOMA, PAPILLARY; CARCINOMA, SIGNET RING CELL; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

MLCS; MLOWN;

EID: 84877112680     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0641-7     Document Type: Article

References (13)

1. Huang CM, Wang JB, Lu HS, Zheng CH, Li P, Xie JW, Zhang XF. Prognostic impact of splenectomy on advanced proximal gastric cancer with no. 10 lymph node metastasis. Chin Med J (Engl). 2009;122:2757-62.
2. Chook YM, Blobel G. Karyopherins and nuclear import. Curr Opin Struct Biol. 2001;11:703-15.
3. Poon IK, Jans DA. Regulation of nuclear transport: central role in development and transformation? Traffic. 2005;6(3):173-86. doi: 10.1111/j.1600-0854.2005.00268.x.
4. Macara IG. Transport into and out of the nucleus. Microbiol Mol Biol Rev. 2001;65:570-94. doi: 10.1128/MMBR.65.4.570-594.2001.
5. Kotera I, Sekimoto T, Miyamoto Y, Saiwaki T, Nagoshi E, Sakagami H, Kondo H, Yoneda Y. Importin alpha transports CaMKIV to the nucleus without utilizing importin beta. EMBO J. 2005;24:942-51. doi: 10.1038/sj.emboj.7600587.
6. Tseng SF, Chang CY, Wu KJ, Teng SC. Importin KPNA2 is required for proper nuclear localization and multiple functions of NBS1. J Biol Chem. 2005;280:39594-600. doi: 10.1074/jbc.M508425200.
7. Zannini L, Lecis D, Lisanti S, Benetti R, Buscemi G, Schneider C, Delia D. Karyopherin-alpha2 protein interacts with Chk2 and contributes to its nuclear import. J Biol Chem. 2003;278:42346-51. doi: 10.1074/jbc.M303304200.
8. Dankof A, Fritzsche FR, Dahl E, Pahl S, Wild P, Dietel M, Hartmann A, Kristiansen G. KPNA2 protein expression in invasive breast carcinoma and matched peritumoral ductal carcinoma in situ. Virchows Arch. 2007;451:877-81.
9. Gluz O, Wild P, Meiler R, Diallo-Danebrock R, Ting E, Mohrmann S, Schuett G, Dahl E, Fuchs T, Herr A, Gaumann A, Frick M, Poremba C, Nitz UA, Hartmann A. Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. Int J Cancer. 2008;123:1433-8. doi: 10.1002/ijc.23628.
10. Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Dürst M, Klinkhammer-Schalke M, Blaszyk H, Knuechel R, Hartmann A, Rosenthal A, Wild PJ. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res. 2006;12:3950-60. doi: 10.1158/1078-0432.CCR-05-2090.
11. Sato F, Abraham JM, Yin J, Kan T, Ito T, Mori Y, Hamilton JP, Jin Z, Cheng Y, Paun B, Berki AT, Wang S, Shimada Y, Meltzer SJ. Polo-like kinase and survivin are esophageal tumor-specific promoters. Biochem Biophys Res Commun. 2006;342:465-71.
12. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006;98:472-82. doi: 10.1093/jnci/djj103.
13. Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H, Rody A, Schaefer KL, Baldus SE, Hartmann A, Wild PJ, Burson M, Gabbert HE, Nitz U, Poremba C. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res. 2007;13:488-97. doi: 10.1158/1078-0432.CCR-06-1842.